Janssen Shares Notable Prostate Cancer Data at ASCO

A little more than a year after winning regulatory approval for a non-metastatic prostate cancer treatment, Janssen Pharmaceuticals is aiming to gain approval for the same medication as a treatment for metastatic castration-sensitive prostate cancer (mCSPC). In April, the Johnson & Johnson subsidiary announced it had submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval for Erleada (apalutamide) for the aforementioned treatment of mCSPC.
Read more...

;